Project description
Innovative vaccine against pancreatic cancer
Pancreatic cancer is a deadly disease for which no treatment is available. CyTuVax B.V. is a biotech enterprise applying depot-formulated cytokines to increase immune responses when used in very high local density. The company developed an innovative technology that can be applied to any vaccine and influence future vaccine technology. The EU-funded PanCaVax project will focus on developing a cost-affordable vaccine for pancreatic cancer. This therapy should substantially improve the life expectancy by extending the median survival rate to at least 12-24 months. The project intends to achieve a favourable clinical outcome and sufficient proof of efficacy for the next steps in Phase IIb/IIIa, regulatory approval and ultimate access to pancreatic cancer patients.
Objective
CyTuVax B.V. is a biotech enterprise founded in Maastricht (the Netherlands) in October 2012. It applies depot-formulated
cytokines (interaction molecules of the immune system), which enhance immune responses in an unprecedented manner
when used in extremely high local density. Single and multi-cytokine combinations can be formulated by simple procedures
and act as strong adjuvants, driving immune responses to their limits. It is a universal, patented platform adjuvant technology
that can be applied to any vaccines and can have great influence on future vaccine technology. CyTuVax achieved the first
clinical proof of concept in a Phase I trial in which 90% of hepatitis B non-responders were successfully vaccinated. Phase II
is on-going. CyTuVax decided now to focus on the challenging problem of developing a vaccine for pancreatic cancer, a
deadly disease for which no curative treatment exists. Its cancer vaccination therapy (PanCaVax) should substantially
improve the life-expectancy by extending the median survival rate to at least 12-24 months. Costs of PanCaVax will be
considerably less compared to checkpoint inhibitor antibodies, with locally strong, but systemically mild, side effects
expected. CyTuVax’ highly motivated team’s next step is to complete the preclinical development of
PanCaVax. Key impact of our innovation would be that it is providing a favorable clinical outcome and sufficient proof of efficacy to obtain financial resources for next steps in Phase IIb/IIIa, regulatory approval and ultimate access to pancreatic cancer patients currently lacking an acceptable therapy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery
- medical and health sciences health sciences infectious diseases
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences clinical medicine oncology pancreatic cancer
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
6229 EV MAASTRICHT
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.